The team of scientists at the Montreal Clinical Research Institute (IRCM), led by Javier Di Noia.
Photo Credit: IRCM
Scientific Frontline: Extended "At a Glance" Summary: Immune System Targeting of Antibody Mutations
The Core Concept: B cells modify their own DNA using the mutagenic enzyme activation-induced cytidine deaminase (AID) to produce a vast diversity of antibodies, a process guided safely by the proteins MLLT1 and MLLT3.
Key Distinction/Mechanism: Unlike uncontrolled genome mutation, the proteins MLLT1 and MLLT3 recognize specific chemical marks on histones and form microscopic molecular condensates; these compartments physically concentrate the naturally inefficient AID enzyme exactly where it is needed, largely sparing the rest of the genome from damage.
Major Frameworks/Components:
- Activation-induced cytidine deaminase (AID): An essential but potentially dangerous enzyme that introduces mutations into antibody genes to improve immune effectiveness.
- MLLT1 and MLLT3 proteins: Histone readers that act as gatekeepers to direct and control AID activity.
- Molecular condensates: Tiny compartments formed by MLLT1 and MLLT3 that gather AID locally to increase the likelihood of targeted mutation.
- Histones: The structural proteins around which DNA is wrapped, providing the chemical markers recognized by the gatekeeper proteins.
Branch of Science: Immunology, Molecular Biology, and Oncology.
Future Application: Inhibiting MLLT1 and MLLT3 may provide a therapeutic strategy to slow the progression of B-cell lymphomas and leukemias by limiting the dangerous chromosomal rearrangements that drive cancerous tumor growth.
Why It Matters: This mechanism explains how evolution balances the need for a highly adaptable immune system with the critical requirement of maintaining overall genomic integrity, offering new conceptual frameworks for treating blood cancers.
Scientists at the Montreal Clinical Research Institute (IRCM) led by Université de Montréal medical professor Javier Di Noia have shed light on a fundamental mystery in immunology: how immune cells manage to concentrate a powerful mutagenic enzyme at precisely defined regions of DNA while largely sparing the rest of the genome from potentially dangerous damage.
Published in the journal Nature, the new research reveals the crucial role of two proteins, MLLT1 and MLLT3, which act as key “gatekeepers” of the activity of the enzyme AID (activation-induced cytidine deaminase). The discovery could help scientists better understand how certain lymphomas and leukemias develop and potentially pave the way for new therapeutic strategies.
Balancing Protection and Risk
To fight infections effectively, B cells—key cells of the immune system—must produce a vast diversity of antibodies. To achieve this, they deliberately modify their own DNA using the enzyme AID, which introduces mutations into antibody genes to improve their effectiveness.
This strategy is essential to immunity, but it comes with a significant risk.
“AID is both essential and potentially dangerous,” said Di Noia, head of the IRCM's Molecular Biology of the B Cell research unit. “If this enzyme acts in the wrong place in the genome, it can damage important genes, cause chromosomal rearrangements, and contribute to the development of B-cell cancers.”
For more than 20 years, scientists have been trying to understand why AID targets certain genes while sparing thousands of others that are also active.
Putting the Enzyme Where It Is Needed
Di Noia's research team discovered that the proteins MLLT1 and MLLT3 play a central role in this selection process.
These proteins recognize specific chemical marks on histones—the proteins around which DNA is wrapped. The scientists showed that regions of the genome with exceptionally high concentrations of MLLT1 and MLLT3 correspond precisely to the sites where AID induces mutations. This was observed in both animal models and humans, including lymphoma cells.
When the researchers simultaneously removed MLLT1 and MLLT3, antibody diversification and AID-induced mutations virtually disappeared, even though the enzyme remained associated with DNA, and the affected genes continued to be expressed.
The study shows that MLLT1 and MLLT3 interact directly with AID and concentrate it locally near targeted genes. These proteins appear to be capable of forming tiny molecular compartments, known as “condensates,” which act as gathering points for the enzyme.
Because AID is naturally inefficient, concentrating it locally greatly increases the likelihood that a mutation will occur.
“Our findings reveal a previously unknown layer of control,” said Di Noia. “Only regions of the genome that accumulate sufficient levels of MLLT1 and MLLT3 can concentrate AID enough to enable efficient mutation. This helps explain how evolution has been able to tolerate such a dangerous enzyme without broadly compromising genome integrity.”
Better Understanding Blood Cancers, Too
This discovery provides new insight into how the immune system harnesses targeted mutations while limiting DNA damage.
It also provides a conceptual framework for understanding why certain regions of the genome are frequently mutated in lymphomas and other cancers derived from B cells.
Particularly promising is the research team’s observation that molecules capable of inhibiting MLLT1 and MLLT3 reduce both AID-dependent mutations and chromosomal translocations associated with cancerous transformation in experimental models.
These proteins could therefore represent future therapeutic targets for slowing the progression of certain lymphomas or limiting the emergence of treatment resistance. Since MLLT1 inhibitors are already in clinical development for certain forms of leukemia, their repurposing could eventually be considered for diseases in which AID plays a key role in tumor progression.
Funding: Funding was provided by the Canadian Institutes of Health Research.
Published in journal: Nature
Title: Histone readers MLLT1 and MLLT3 concentrate AID to confer locus specificity
Authors: Noé Seija, Sophia Gannon, Kíra A. Häfner, Tim M. Gemeinhardt, Jana Ridani, Diego Alvarez, Mélanie Provencher, Poorani Ganesh Subramani, Christian Poitras, Eva-Maria Piskor, Tarik Möröy, Nicholas Vonniessen, Bruce Mazer, Marcelo A. Navarrette, Nicole J. Francis, François Robert, and Javier M. Di Noia
Source/Credit: Université de Montréa
Edited by: Scientific Frontline
Reference Number: imgy100126_01
